A standard PSA blood test measures several circulating forms of prostate-specific antigen together. Free PSA is the portion circulating without being bound to certain blood proteins. Measuring free PSA alongside total PSA can provide additional information when the total PSA alone cannot clearly distinguish benign prostate conditions from prostate-cancer risk.
01. Free PSA: Definition, Blood Forms and Clinical Meaning
What exactly is free PSA?
PSA stands for prostate-specific antigen, a protein enzyme produced mainly by epithelial cells within the prostate gland.
Most PSA is normally secreted into prostate fluid and ultimately semen.
Only a small amount enters the bloodstream.
Once PSA reaches the blood, it does not all circulate in the same molecular form.
Some PSA becomes attached to serum proteins. Another portion remains unbound.
That unbound portion is called free PSA, often abbreviated fPSA.
A laboratory can measure both:
- total PSA, which includes free PSA plus the clinically measurable protein-complexed PSA;
- and free PSA, which measures only the unbound fraction.
Why does PSA become free or protein-bound in the blood?
PSA is a protease, meaning it is an enzyme capable of breaking down proteins.
In semen, PSA has a normal role in helping liquefy the seminal coagulum after ejaculation.
When active PSA enters the bloodstream, naturally occurring protease inhibitors can bind to it.
One important measurable complex is PSA bound to alpha-1-antichymotrypsin.
Other circulating PSA molecules are enzymatically inactive or otherwise remain unbound and are detected as free PSA.
The balance between these molecular forms differs between benign and malignant prostate conditions.
That difference is why free PSA became clinically useful as an additional prostate-cancer risk marker.
02. How Do Free PSA and Total PSA Differ?
What is included in total PSA?
The standard PSA value most patients receive is total PSA, often abbreviated tPSA.
Total PSA combines the clinically measurable PSA circulating in different forms.
Conceptually:
If a laboratory reports:
- total PSA = 6.0 ng/mL;
- and free PSA = 1.2 ng/mL;
the free PSA concentration represents only one portion of the total measurement.
The two results should not be compared as though they were independent tests measuring unrelated substances.
What is percent-free PSA?
Percent-free PSA compares the amount of free PSA with the total PSA.
It is calculated as:
Why is the percentage often more useful than the free PSA number alone?
The absolute free PSA level naturally tends to increase when total PSA increases.
For example, a free PSA of 1 ng/mL has a very different meaning when:
- total PSA is 2 ng/mL;
- compared with total PSA of 10 ng/mL.
The first example would contain a much larger free fraction than the second.
By converting free PSA into a proportion of total PSA, the clinician can ask whether the patient’s circulating PSA pattern is more commonly associated with benign prostate tissue or with prostate cancer.
Older and modern studies consistently show that men with prostate cancer tend, on average, to have a lower percentage of free PSA than men with benign prostate conditions.
However, there is substantial overlap between the groups.
Percent-free PSA therefore changes probability rather than establishing pathology.
| Measurement | What it measures | Typical unit | Main clinical role |
|---|---|---|---|
| Total PSA | Overall clinically measurable circulating PSA. | ng/mL | Primary PSA measurement used in prostate screening and evaluation. |
| Free PSA | PSA circulating without being bound to certain serum proteins. | ng/mL | Measured so its proportion relative to total PSA can be assessed. |
| Percent-free PSA | Free PSA divided by total PSA. | % | Helps refine cancer probability when total PSA alone is difficult to interpret. |
| Complexed PSA | PSA attached to measurable serum proteins. | ng/mL | Contributes to total PSA and differs in relative proportion between benign and malignant conditions. |
03. When Is Free PSA Measured and What Can Affect Its Interpretation?
When do clinicians usually order free PSA?
Free PSA is most useful when the total PSA is elevated enough to create concern but not so informative that the next step is already obvious.
Historically, the strongest evidence developed in men with total PSA between approximately 4 and 10 ng/mL, sometimes called the diagnostic “gray zone.”
More recent biomarker studies have also evaluated free-to-total PSA in broader intermediate ranges such as approximately 2–10 ng/mL.
This is the range where benign prostate enlargement and prostate cancer frequently overlap in total PSA concentration.
Free PSA can therefore help answer a narrower question:
Does the molecular pattern of this PSA make benign prostate disease relatively more likely or prostate cancer relatively more concerning?
It cannot answer that question with certainty.
Why is free PSA often higher in benign prostate enlargement?
Studies consistently show that men with BPH tend to have a greater proportion of circulating PSA in the free form than men with prostate cancer.
The biological explanation is more complex than simply saying that “benign PSA is free” and “cancer PSA is bound.”
Both benign and malignant prostates produce multiple PSA forms.
Differences in glandular structure, enzyme activation, PSA processing and interaction with serum protease inhibitors influence the proportions measured in blood.
As a practical result, a higher free-to-total PSA proportion is more commonly associated with benign disease, while a lower proportion raises cancer probability.
Do prostate size and age affect free PSA?
Yes.
Free PSA measurements do not exist independently of the rest of prostate biology.
Research has shown that percent-free PSA can increase with both age and prostate volume.
This is particularly relevant because benign prostate growth becomes more common with aging.
A large prostate can contribute both:
- a higher total PSA;
- and a higher relative free PSA fraction.
Prostate volume should therefore remain part of the clinical picture rather than assuming that the free PSA result has corrected for every effect of benign gland growth.
The gland-volume measurement itself is explained in How Is Prostate Volume Measured?
Can inflammation and temporary PSA changes affect free PSA interpretation?
Yes.
Conditions that alter total PSA can also complicate interpretation of its individual molecular fractions.
Examples include:
- prostatitis;
- urinary tract infection;
- acute urinary retention;
- recent prostate biopsy;
- recent urinary manipulation;
- and normal biological or laboratory variation.
For this reason, a free PSA result should not be used to rescue or reinterpret a total PSA value that was drawn under poor testing conditions.
When the total PSA itself needs confirmation, repeat testing should be performed appropriately before relying heavily on derived PSA measurements.
Do finasteride and dutasteride affect free PSA interpretation?
The BPH medications finasteride and dutasteride reduce the measured total PSA substantially during sustained therapy.
Current EAU guidance describes an average reduction of approximately 50%.
Medication history therefore remains essential whenever any PSA-derived measurement is being interpreted.
Patients should tell the clinician when treatment began and provide previous PSA results when available.
A free PSA value should not be interpreted from an internet percentage table while ignoring treatment with a PSA-suppressing medication.
04. How Does Free PSA Affect Prostate-Cancer Risk Assessment?
Does a lower free PSA mean prostate cancer is present?
No.
A lower free-to-total PSA proportion is associated with a higher probability of prostate cancer in populations of men undergoing evaluation, particularly when total PSA is in an intermediate range.
But the distributions overlap.
Some men with benign prostate disease have low percent-free PSA, while some men with prostate cancer have relatively high percentages.
The result should therefore be used as one part of a multivariable assessment.
Modern risk assessment can incorporate:
- age;
- total PSA;
- percent-free PSA;
- prostate volume and PSA density;
- digital rectal examination;
- family history;
- genetic risk;
- previous biopsy history;
- other blood or urine biomarkers;
- and prostate MRI.
Is free PSA still useful now that prostate MRI is widely used?
Yes, but its role has changed.
Modern prostate-cancer diagnosis increasingly uses sequential risk assessment rather than relying on one PSA-derived cutoff.
Current EAU guidance allows additional serum or urine biomarkers to help determine biopsy indication in men with an elevated PSA.
However, newer blood tests can incorporate more information than percent-free PSA alone.
For example:
- the Prostate Health Index (PHI) combines total PSA, free PSA and the [-2]proPSA isoform;
- the 4Kscore includes total PSA, free PSA and additional kallikrein measurements together with clinical factors;
- and some validated prostate-cancer risk calculators include percent-free PSA as one of several predictors.
EAU evidence indicates that PHI and the 4Kscore outperform free-to-total PSA alone for prediction of clinically significant prostate cancer in men with PSA approximately 2–10 ng/mL.
Free PSA has therefore not become irrelevant. Instead, it is one component of an increasingly layered diagnostic pathway.
Can free PSA prevent unnecessary prostate biopsies?
It can help.
One reason free PSA testing was developed was to improve the specificity of total PSA in men whose values fall into an intermediate range.
Early prospective studies showed that using percent-free PSA could reduce some negative biopsies while maintaining relatively high cancer-detection sensitivity.
However, the exact performance depends on:
- the total PSA range;
- the percentage threshold selected;
- age;
- prostate volume;
- biopsy history;
- the laboratory assay;
- and the prevalence of prostate cancer in the population being tested.
For that reason, one percentage should not be interpreted as a universal biopsy rule.
Modern MRI-based evaluation and multivariable risk calculators can provide information that was not available when the original free PSA studies were performed.
What is the next question after understanding free PSA?
Once the distinction between free PSA and total PSA is clear, the next question is how the percentage should be interpreted.
That requires looking at:
- how percent-free PSA is calculated;
- why lower percentages tend to increase cancer probability;
- how commonly used percentage ranges are interpreted;
- why those ranges are not absolute cancer cutoffs;
- and when the ratio is useful enough to change the next diagnostic step.
The next FBU guide covers that specific clinical question in Percent-Free PSA: Calculation, Interpretation and Cancer-Risk Ranges.
Free PSA at a Glance
| Question | Practical answer |
|---|---|
| What is free PSA? | PSA circulating in blood without being bound to certain serum proteins. |
| What is total PSA? | The overall clinically measurable circulating PSA, including free and protein-complexed forms. |
| Is free PSA different from total PSA? | Yes. Free PSA is one component of the total PSA measurement. |
| How is free PSA reported? | It can be reported as an absolute concentration in ng/mL. |
| What is percent-free PSA? | Free PSA divided by total PSA and multiplied by 100. |
| Is free PSA the same as percent-free PSA? | No. One is an absolute concentration; the other is a proportion. |
| Does BPH tend to produce more free PSA? | Men with benign prostate enlargement tend, on average, to have a higher free-to-total PSA proportion. |
| Does prostate cancer tend to have lower free PSA? | Prostate cancer is generally associated with a lower percent-free PSA than benign prostate disease. |
| Does low free PSA prove cancer? | No. |
| Does high free PSA rule cancer out? | No. |
| When is free PSA most useful? | When total PSA is in an intermediate range and additional risk discrimination could influence further evaluation. |
| What PSA range has the strongest historical evidence? | Much of the classic evidence concerns total PSA around 4–10 ng/mL, with modern biomarker research often evaluating roughly 2–10 ng/mL. |
| Does prostate size affect free PSA? | Yes. Age and prostate volume can influence the free-to-total PSA proportion. |
| Can free PSA replace MRI? | No. They provide different types of information. |
| Can free PSA replace biopsy? | No. Biopsy provides tissue diagnosis when required. |
| Is free PSA used in newer blood tests? | Yes. Free PSA contributes to multivariable tests such as PHI and the 4Kscore. |
Summary
- Free PSA is prostate-specific antigen circulating without being bound to certain serum proteins.
- Total PSA includes the clinically measured free and protein-complexed PSA fractions.
- Free PSA is normally reported in ng/mL.
- Percent-free PSA is calculated by dividing free PSA by total PSA and multiplying by 100.
- Free PSA and percent-free PSA are related but different laboratory results.
- The percentage is usually more clinically informative than the absolute free PSA concentration alone.
- Men with BPH tend to have a higher proportion of free PSA than men with prostate cancer.
- Men with prostate cancer tend, on average, to have a lower free-to-total PSA ratio.
- There is substantial overlap between benign and malignant prostate disease.
- A low percent-free PSA therefore increases cancer probability but does not diagnose cancer.
- A high percent-free PSA can reduce cancer probability but does not exclude cancer.
- Free PSA is most useful when total PSA is in an intermediate range where benign conditions and prostate cancer overlap.
- Much of the classic evidence concerns men with total PSA between approximately 4 and 10 ng/mL.
- Modern biomarker studies often evaluate broader intermediate PSA ranges around 2–10 ng/mL.
- Age and prostate volume can influence the free-to-total PSA proportion.
- Temporary PSA-changing conditions can complicate interpretation of both total and free PSA.
- Finasteride and dutasteride lower total PSA substantially and must be considered when interpreting PSA-derived measurements.
- Modern prostate-cancer assessment increasingly combines PSA measurements with prostate volume, PSA density, clinical risk calculators, additional biomarkers and MRI.
- PHI includes total PSA, free PSA and [-2]proPSA.
- The 4Kscore includes free and total PSA together with additional kallikrein and clinical information.
- Current EAU evidence indicates that PHI and 4Kscore provide better prediction of clinically significant prostate cancer than free-to-total PSA alone in appropriate intermediate-PSA populations.
- Free PSA is a risk-refinement measurement, not a stand-alone prostate-cancer diagnosis.
Educational disclaimer: This article provides general medical education about free PSA. A free PSA or percent-free PSA result should not be used alone to diagnose or exclude prostate cancer or to decide whether prostate biopsy is required. Interpretation depends on total PSA, age, prostate volume, previous results, medications, temporary PSA-changing conditions, family and genetic risk, examination findings and other diagnostic information.
Explore the PSA Pathway
For the complete screening and diagnostic framework, return to PSA Testing and Prostate Screening.
For the basic blood-test definition, see What Is PSA?
For PSA reference interpretation, see What Is a Normal PSA Level? and PSA Levels by Age.
For benign and temporary reasons total PSA may rise, see What Causes a High PSA? and Can PSA Be High Without Prostate Cancer?
For interpretation of a lower total PSA result, see What Does a Low PSA Mean?
Because benign prostate volume can influence both total and free PSA, see BPH and Enlarged Prostate and How Is Prostate Volume Measured?
The next guide explains Percent-Free PSA: Calculation, Interpretation and Cancer-Risk Ranges.
Evidence Sources
- National Cancer Institute. Definition of Free PSA.
- European Association of Urology. Prostate Cancer Guidelines — PSA, Free PSA, PHI, 4Kscore and Biomarker-Based Risk Assessment.
- Catalona WJ, et al. Analysis of Percent Free PSA for Prostate Cancer Detection: Influence of Total PSA, Prostate Volume and Age.
- Measurement of the Proportion of Free to Total PSA Improves Diagnostic Performance in the Intermediate PSA Range.
- Lee R, et al. Meta-analysis of the Performance Characteristics of the Free PSA Test.
- Bruzzese D, et al. Prostate Health Index vs Percent-Free PSA for Prostate Cancer Detection: Systematic Review and Meta-analysis.
